Dr. Martens (LON:DOCS - Get Free Report) was upgraded by research analysts at Peel Hunt to a "buy" rating in a research note issued to investors on Monday, MarketBeat reports.
Other analysts also recently issued research reports about the stock. Royal Bank Of Canada decreased their price objective on shares of Dr. Martens from GBX 7,000 to GBX 6,000 and set a "sector perform" rating on the stock in a report on Monday, May 19th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Dr. Martens in a research report on Friday, July 11th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Dr. Martens presently has an average rating of "Hold" and a consensus target price of GBX 6,000.
Check Out Our Latest Stock Report on DOCS
Dr. Martens Stock Up 1.3%
DOCS stock opened at GBX 88.85 on Monday. The company has a market cap of £862.52 million, a P/E ratio of 12.60, a P/E/G ratio of 6.40 and a beta of 0.11. Dr. Martens has a 52 week low of GBX 43.02 and a 52 week high of GBX 90. The company's 50-day moving average price is GBX 77.72 and its 200 day moving average price is GBX 65.59. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27.
Dr. Martens (LON:DOCS - Get Free Report) last released its quarterly earnings data on Thursday, June 5th. The company reported GBX 2.40 EPS for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. On average, research analysts expect that Dr. Martens will post 2.5809394 earnings per share for the current fiscal year.
Dr. Martens Company Profile
(
Get Free Report)
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.
Further Reading
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access